Upadacitinib
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Prurigo Nodularis
Conditions
Prurigo Nodularis
Trial Timeline
Apr 9, 2024 → Jan 1, 2026
NCT ID
NCT06773403About Upadacitinib
Upadacitinib is a approved stage product being developed by AbbVie for Prurigo Nodularis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06773403. Target conditions include Prurigo Nodularis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04159597 | Pre-clinical | Active |
| NCT06332534 | Phase 3 | Recruiting |
| NCT06773403 | Approved | Recruiting |
| NCT05782907 | Phase 3 | Active |
| NCT05507580 | Approved | Completed |
| NCT05094128 | Pre-clinical | Recruiting |
| NCT04195698 | Phase 3 | Completed |
| NCT03725007 | Phase 1 | Active |
Competing Products
20 competing products in Prurigo Nodularis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Vixarelimab + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| Pimecrolimus + Hydrocortisone + Pimecrolimus | Novartis | Phase 2 | 52 |
| Rocatinlimab + Placebo | Amgen | Phase 3 | 76 |
| Abrocitinib | Pfizer | Phase 2 | 51 |
| Dupilumab SAR231893 (REGN668) | Sanofi | Pre-clinical | 22 |
| Dupilumab | Sanofi | Phase 3 | 76 |
| Dupilumab | Sanofi | Pre-clinical | 22 |
| Dupilumab | Sanofi | Pre-clinical | 22 |
| Ruxolitinib Cream 1.5% | Incyte | Phase 1 | 30 |
| Ruxolitinib Cream + Vehicle Cream | Incyte | Phase 3 | 74 |
| INCB054707 + Placebo | Incyte | Phase 2 | 49 |
| Povorcitinib + Placebo | Incyte | Phase 3 | 74 |
| Povorcitinib + Placebo | Incyte | Phase 3 | 74 |
| Ruxolitinib Cream + Vehicle Cream | Incyte | Phase 3 | 74 |
| CDX-0159 + Normal saline | Celldex Therapeutics | Phase 1 | 28 |
| barzolvolimab | Celldex Therapeutics | Phase 2 | 47 |
| nalbuphine HCl ER tablets 90 mg BID + nalbuphine HCl ER tablets 180 mg BID + Placebo tablets BID | Trevi Therapeutics | Phase 2/3 | 60 |
| nalbuphine HCl ER | Trevi Therapeutics | Phase 2/3 | 60 |
| Nalbuphine ER Tablets + Placebo Tablets | Trevi Therapeutics | Phase 2/3 | 60 |
| serlopitant + Placebo | Vyne Therapeutics | Phase 2 | 44 |